#biotech

🏢Release 📈 Stocks

XtalPi Partners with Laboratoires Pierre Fabre for AI Drug Discovery

November 9, 2026 (1 day ago)

XtalPi and Laboratoires Pierre Fabre have entered a strategic partnership to accelerate drug discovery in oncology and other therapeutic areas using AI…

2228.HK

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

XtalPi Partners With Pierre Fabre for AI-Driven Oncology Drug Discovery

November 9, 2026 (1 day ago)

XtalPi and Pierre Fabre have entered an AI-led drug discovery partnership targeting complex oncology research, utilizing XtalPi's robotics platform to accelerate the…

2228.HK

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

XtalPi Partners With Laboratoires Pierre Fabre for AI Drug Discovery

November 9, 2026 (1 day ago)

XtalPi and Laboratoires Pierre Fabre have entered an AI-driven drug discovery partnership targeting oncology and other therapeutic areas, featuring an undisclosed upfront…

2228.HK

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Inductive Wins OpenADMET Challenge, Outpacing NVIDIA and Recursion

November 6, 2026 (4 days ago)

Inductive topped the OpenADMET CYP Direct Inhibition Challenge, marking its fourth straight win in AI drug discovery benchmarks while besting industry peers…

RXRX NVDA

🌍 US Read More →

🏢Release 📈 Stocks

Zydus Lifesciences Reports Positive Phase 2b Data for Saroglitazar in MASH

November 6, 2026 (4 days ago)

Zydus Lifesciences' saroglitazar demonstrated significant efficacy in resolving steatohepatitis in a Phase 2b MASH trial, supporting plans for larger, long-term clinical studies.

ZYDUSLIFE

🌍 IN Read More →

🏛️Filing 📈 Stocks

Immunocore Holdings Files 8-K Reporting Results of Operations

November 6, 2026 (4 days ago)

Immunocore Holdings plc filed an 8-K with the SEC on November 6, 2026, providing an update on its results of operations and…

IMCR

🌍 US Read More →

🏢Release 📈 Stocks

Klaria Pharma Holding Sets 6 November as Final Day for 147.6 MSEK Rights Issue

November 6, 2026 (4 days ago)

Klaria Pharma Holding reaches the final subscription deadline for its 147.6 MSEK rights issue, aimed at bolstering liquidity for upcoming commercial milestones…

KLAR

🌍 EUROPE Read More →

📰News 📈 Stocks

Rafael Holdings Faces Pomerantz Investigation Following Failed Phase 3 Trial

November 6, 2026 (4 days ago)

Rafael Holdings is under scrutiny by Pomerantz LLP after its Phase 3 TransportNPC study missed primary endpoints, causing a 34.98% stock price…

RFL

🌍 US Read More →

🏢Release 📈 Stocks

Johnson & Johnson Receives FDA Accelerated Approval for RYBREVANT FASPRO

November 6, 2026 (4 days ago)

Johnson & Johnson secures FDA accelerated approval for RYBREVANT FASPRO in head and neck cancer, marking the drug's first expansion beyond non-small…

JNJ

🌍 US Read More →

🏢Release 📈 Stocks

AusperBio Reports 15-Month Functional Cure Durability for AHB-137 in CHB

November 6, 2026 (4 days ago)

AusperBio's AHB-137 shows sustained functional cure in chronic hepatitis B patients for up to 15 months post-treatment, bolstering the company's Phase 3…

INR

🌍 US Read More →

⚡Ad-hoc 📈 Stocks

BioInvent Sets SEK 430 Million Rights Issue Terms With Full Guarantee

November 5, 2026 (4 days ago)

BioInvent secures full backing for a SEK 430 million rights issue at SEK 1.00 per share, aiming to fund clinical development of…

BINV

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Curis Schedules Third Quarter 2026 Earnings Release for November 12

November 5, 2026 (4 days ago)

Curis will report its Q3 2026 financial results on November 12, 2026, followed by a conference call at 4:30 p.m. ET to…

CRIS

🌍 US Read More →